Company news
Hainan Huluwa Pharmaceutical Group Co. Ltd. Class A (SSE:605199) news
Hainan Huluwa Pharmaceutical Group Co. Ltd. Class A news releases on 6ix. Latest, Aug 29, 2026: "HAINAN HULUWA PHARMACEUTICAL GROUP CO., LTD."Announcement…
Press releases & updates
"HAINAN HULUWA PHARMACEUTICAL GROUP CO., LTD."Announcement on Progress of Matters Related to the Imposition of Other Risk Warning on the Company's Shares
August 28, 2026
"HAINAN HULUWA PHARMACEUTICAL GROUP CO., LTD."Semi-annual Report for 2026
August 26, 2026
"HAINAN HULUWA PHARMACEUTICAL GROUP CO., LTD."Rectification Report in Response to Warning Letter from Hainan CSRC Office
August 14, 2026
"HAINAN HULUWA PHARMACEUTICAL GROUP CO., LTD."Announcement on Change of Sponsor Representative for Continuous Supervision
August 7, 2026
"HAINAN HULUWA PHARMACEUTICAL GROUP CO., LTD."Announcement on Obtaining Drug Registration Certificate by the Company and Its Wholly-owned Subsidiary
August 6, 2026
"HAINAN HULUWA PHARMACEUTICAL GROUP CO., LTD."Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
July 29, 2026
"HAINAN HULUWA PHARMACEUTICAL GROUP CO., LTD."Announcement on Providing Guarantee for Wholly-owned Subsidiary
July 24, 2026
"HAINAN HULUWA PHARMACEUTICAL GROUP CO., LTD."Announcement on Reply to Letter of Supervision and Inquiry on Information Disclosure of 2025 Annual Report
July 21, 2026
"HAINAN HULUWA PHARMACEUTICAL GROUP CO., LTD."Announcement on Receipt of the Administrative Penalty Decision by the Company and Relevant Responsible Persons
July 17, 2026
"HAINAN HULUWA PHARMACEUTICAL GROUP CO., LTD."Announcement on Undertakings by Controlling Shareholder and Actual Controller Not to Reduce Their Shareholdings in the Company
July 15, 2026
"HAINAN HULUWA PHARMACEUTICAL GROUP CO., LTD."Semi-annual Performance Forecast for 2026
July 14, 2026
"HAINAN HULUWA PHARMACEUTICAL GROUP CO., LTD."Announcement on Re-appointment of Accounting Firm for 2026
July 13, 2026
"HAINAN HULUWA PHARMACEUTICAL GROUP CO., LTD."Announcement on Obtaining Drug Registration Certificate by the Company and Its Wholly-owned Subsidiaries
July 10, 2026
"HAINAN HULUWA PHARMACEUTICAL GROUP CO., LTD."Announcement on Abnormal Fluctuations in Stock Trading
July 3, 2026
"Hainan Huluwa Pharmaceutical Group Co., Ltd."Announcement on Progress in Implementing Other Risk Warnings for the Company's Stocks
June 30, 2026
Announcement on Using Partial Idle Raised Funds to Temporarily Supplement Current Capital
June 26, 2026
Announcement on Return of Raised Funds Temporarily Used to Supplement Current Capital
June 25, 2026
Announcement on Change of Sponsor Representative for Continuous Supervision
June 8, 2026
Announcement on Wholly-Owned Subsidiary Obtaining Drug Registration Certificate for Potassium Chloride Oral Solution
June 1, 2026
Announcement on Pledge of Partial Shares of Controlling Shareholder
May 29, 2026
Announcement on Freezing Release of Some Shares of Controlling Shareholder
May 25, 2026
Announcement on Obtaining the Drug Registration Certificate for Zoledronic Acid Concentrate for Injection
May 22, 2026
Announcement on Resignation of Independent Director
May 21, 2026
Announcement on Concurrent Implementation of Other Risk Warnings for the Company’s Shares
May 20, 2026
Announcement on Pledge of Partial Shares of Shareholder
May 14, 2026
Announcement on Judicial Freeze of Part of the Controlling Shareholder's Shares, Progress in Enforcement, and Execution of Settlement Agreement
May 11, 2026
Announcement on Proposed Inclusion of Company Drugs in the Centralized Volume Procurement of National Chinese Patent Medicine Procurement Alliance (4th Round)
May 6, 2026
Indicative Announcement on the Company Being Subject to Compulsory Enforcement
April 30, 2026
Indicative Announcement on the Completion of Judicial Auction and Transfer of Some Shares Held by Controlling Shareholder and Equity Change
April 29, 2026
Announcement on Confirming Remunerations for Directors and Senior Management Members in 2025 and 2026 Remuneration Plan
April 28, 2026
Announcement on Freezing of Some Shares of Controlling Shareholder
April 22, 2026
Announcement on Company Re-certified as High-tech Enterprise
April 7, 2026
Announcement on Progress in Implementing Other Risk Warnings for the Company's Stocks
March 30, 2026
Announcement on Obtaining Drug Registration Certificate
March 20, 2026
Announcement on Wholly-owned Subsidiary Obtaining Drug Registration Certificate for Ambroxol Hydrochloride Oral Drops
March 4, 2026
Announcement on Progress in Judicial Auction of Some Shares Held by Controlling Shareholder
March 2, 2026
Announcement on Obtaining the Drug Registration Certificate for Ipratropium Bromide Solution for Inhalation
February 24, 2026
Announcement on Wholly-Owned Subsidiary Obtaining Drug Registration Certificate for Compound Polyethylene Glycol (3350) Electrolyte Oral Solution
February 6, 2026
Announcement on Expected Loss in Performance for 2025
January 30, 2026
Announcement on Providing Guarantee for Wholly-owned Subsidiary by Guangxi Weiwei Pharmaceutical Co., Ltd.
January 29, 2026
Indicative Announcement on Upcoming Judicial Auction of Some Shares Held by Controlling Shareholder
January 20, 2026
Announcement on Obtaining Drug Registration Certificate for Levosalbutamol Hydrochloride Nebuliser Solution
January 5, 2026
Announcement on Abnormal Fluctuations in Stock Trading
December 31, 2025
Announcement on Receiving Notice of Case Filing from China Securities Regulatory Commission
December 28, 2025
Notice on Convening the 3rd Extraordinary General Meeting in 2025
December 15, 2025
Announcement on Judicial Freezing of Some Shares of Controlling Shareholder
December 5, 2025
Announcement on Providing Guarantee for Wholly-owned Subsidiary
December 1, 2025
Announcement on Progress in Signing of Technology Cooperation Contract with a Related Party and Related Party Transaction
October 31, 2025
Announcement on Appointment of Deputy General Manager
October 30, 2025
Announcement on Obtaining Notice of Approval for Drug Clinical Trials
October 27, 2025